Elliss-Brookes L, McPhail S, Ives A, Greenslade M, Shelton J, Hiom S, et al. Routes to diagnosis for cancer—determining the patient journey using multiple routine data sets. Br J Cancer. 2012;107:1220–6. https://doi.org/10.1038/bjc.2012.408.
Article CAS PubMed PubMed Central Google Scholar
Abel GA, Shelton J, Johnson S, Elliss-Brookes L, Lyratzopoulos G. Cancer-specific variation in emergency presentation by sex, age and deprivation across 27 common and rarer cancers. Br J Cancer. 2015;112:S129–36. https://doi.org/10.1038/bjc.2015.52.
Article PubMed PubMed Central Google Scholar
Zhou Y, Abel GA, Hamilton W, Pritchard-Jones K, Gross CP, Walter FM, et al. Diagnosis of cancer as an emergency: a critical review of current evidence. Nat Rev Clin Oncol. 2017;14:45–56. https://doi.org/10.1038/nrclinonc.2016.155.
Howell D, Smith A, Appleton S, Bagguley T, Macleod U, Cook G, et al. Multiple myeloma: routes to diagnosis, clinical characteristics and survival - findings from a UK population-based study. Br J Haematol. 2017;177:67–71. https://doi.org/10.1111/bjh.14513.
Article PubMed PubMed Central Google Scholar
Howell DA, Hart RI, Smith AG, Macleod U, Patmore R, Cook G, et al. Myeloma: patient accounts of their pathways to diagnosis. PLoS One. 2018;13:e0194788. https://doi.org/10.1371/journal.pone.0194788.
Article CAS PubMed PubMed Central Google Scholar
Kariyawasan CC, Hughes DA, Jayatillake MM, Mehta AB. Multiple myeloma: causes and consequences of delay in diagnosis. QJM. 2007;100:635–40. https://doi.org/10.1093/qjmed/hcm077.
Article CAS PubMed Google Scholar
Khan M, Adil SF, Alkhathlan HZ, Tahir MN, Saif S, Khan M, et al. COVID-19: a global challenge with old history, epidemiology and progress so far. Molecules. 2020;26:39. https://doi.org/10.3390/molecules26010039.
Article CAS PubMed PubMed Central Google Scholar
Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong K, et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020;136:3033–40. https://doi.org/10.1182/blood.2020008150.
Article CAS PubMed PubMed Central Google Scholar
Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020;21:1023–34. https://doi.org/10.1016/S1470-2045(20)30388-0.
Article CAS PubMed PubMed Central Google Scholar
Martínez-López J, Mateos MV, Encinas C, Sureda A, Hernández-Rivas JÁ, Lopez de la Guía A, et al. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. Blood Cancer J. 2020;10:103. https://doi.org/10.1038/s41408-020-00372-5.
Article PubMed PubMed Central Google Scholar
Lai AG, Pasea L, Banerjee A, Hall G, Denaxas S, Chang WH, et al. Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study. BMJ Open. 2020;10:e043828. https://doi.org/10.1136/bmjopen-2020-043828.
Nicholson BD, Ordóñez-Mena JM, Lay-Flurrie S, Sheppard JP, Liyanage H, McGagh D, et al. Consultations for clinical features of possible cancer and associated urgent referrals before and during the COVID-19 pandemic: an observational cohort study from English primary care. Br J Cancer. 2022;126:948–56. https://doi.org/10.1038/s41416-021-01666-6.
Article CAS PubMed Google Scholar
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48. https://doi.org/10.1016/S1470-2045(14)70442-5.
Sive J, Cuthill K, Hunter H, Kazmi M, Pratt G, Smith D, et al. Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline. Br J Haematol. 2021;193:245–68. https://doi.org/10.1111/bjh.17410.
Cook G, Royle KL, Pawlyn C, Hockaday A, Shah V, Kaiser MF, et al. A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematol. 2019;6:e154–66. https://doi.org/10.1016/S2352-3026(18)30220-5.
Article PubMed PubMed Central Google Scholar
Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125:2068–74. https://doi.org/10.1182/blood-2014-12-615187.
Article CAS PubMed PubMed Central Google Scholar
Redder L, Klausen TW, Vangsted AJ, Gregersen H, Andersen NF, Pedersen RS, et al. Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registry. Br J Haematol. 2021;193:119–24. https://doi.org/10.1111/bjh.16806.
Djebbari F, Rampotas A, Panitsas F, Lim WY, Lees C, Tsagkaraki I, et al. Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients. PLoS One. 2022;17:e0262388 https://doi.org/10.1371/journal.pone.0262388.
Article CAS PubMed PubMed Central Google Scholar
Djebbari F, Panitsas F, Sharpley FA, Rampotas A, Larham J, Moore S, et al. Myeloma care adaptations in the UK during SARS-CoV-2 pandemic: challenges and measurable outcomes. Eur J Haematol. 2020;105:662–6. https://doi.org/10.1111/ejh.13479.
Article CAS PubMed PubMed Central Google Scholar
Freeman CL, Mikhael J. COVID-19 and myeloma: what are the implications for now and in the future? Br J Haematol. 2020;190:173–8. https://doi.org/10.1111/bjh.16815.
Article CAS PubMed PubMed Central Google Scholar
Fox L, Monroy-Iglesias MJ, Aggarwal A, Haire K, Purushotham A, Spicer J, et al. Association between COVID-19 burden and delays to diagnosis and treatment of cancer patients in England. J Cancer Policy. 2022;31:100316. https://doi.org/10.1016/j.jcpo.2021.100316.
Kanellias N, Ntanasis-Stathopoulos I, Gavriatopoulou M, Koutoulidis V, Fotiou D, Migkou M, et al. Newly diagnosed multiple myeloma patients with skeletal-related events and abnormal MRI pattern have poor survival outcomes: a prospective study on 370 patients. J Clin Med. 2022;11:3088. https://doi.org/10.3390/jcm11113088.
Article CAS PubMed PubMed Central Google Scholar
Jordan K, Proskorovsky I, Lewis P, Ishak J, Payne K, Lordan N, et al. Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study. Support Care Cancer. 2014;22:417–26. https://doi.org/10.1007/s00520-013-1991-4.
Cheng KK, Lee DT. Effects of pain, fatigue, insomnia, and mood disturbance on functional status and quality of life of elderly patients with cancer. Crit Rev Oncol Hematol. 2011;78:127–37. https://doi.org/10.1016/j.critrevonc.2010.03.002.
Groot MT, Huijgens PC, Wijermans PJ, Uyl-de Groot CA. Costs of multiple myeloma and associated skeletal-related events in The Netherlands. Expert Rev Pharmacoecon Outcomes Res. 2004;4:565–72. https://doi.org/10.1586/14737167.4.5.565.
Gulla A, Anderson KC. Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica. 2020;105:2358–67. https://doi.org/10.3324/haematol.2020.247015.
Article CAS PubMed PubMed Central Google Scholar
Cook G, John Ashcroft A, Pratt G, Popat R, Ramasamy K, Kaiser M, et al. United Kingdom Myeloma Forum. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. Br J Haematol. 2020;190:e83–6. https://doi.org/10.1111/bjh.16874.
Article CAS PubMed PubMed Central Google Scholar
Booth S, Curley HM, Varnai C, Arnold R, Lee LYW, Campton NA, et al. Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy. Br J Haematol. 2022;196:892–901. https://doi.org/10.1111/bjh.17937.
Article CAS PubMed Google Scholar
Pawlyn C, Cairns D, Kaiser M, Striha A, Jones J, Shah V, et al. The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia. 2020;34:604–12. https://doi.org/10.1038/s41375-019-0595-5.
Article CAS PubMed Google Scholar
Martinez-Lopez J, Hernandez-Ibarburu G, Alonso R, Sanchez-Pina JM, Zamanillo I, Lopez-Muñoz N, et al. Impact of COVID-19 in patients with multiple myeloma based on a global data network. Blood Cancer J. 2021;11:198. https://doi.org/10.1038/s41408-021-00588-z.
Article PubMed PubMed Central Google Scholar
Terpos E, Engelhardt M, Cook G, Gay F, Mateos MV, Ntanasis-Stathopoulos I, et al. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2020;34:2000–11. https://doi.org/10.1038/s41375-020-0876-z.
Article CAS PubMed PubMed Central Google Scholar
Parrondo RD, Ailawadhi S, Sher T, Chanan-Khan AA, Roy V. Autologous stem-cell transplantation for multiple myeloma in the era of novel therapies. JCO Oncol Pr. 2020;16:56–66. https://doi.org/10.1200/JOP.19.00335.
留言 (0)